Tabla de Contenidos:
  • Preface
  • 1
  • Fragment Descriptors in SAR/QSAR/QSPR studies, molecular similarity analysis and in virtual screening
  • Introduction
  • Historical survey
  • Main characteristics of Fragment Descriptors
  • Types of Fragments
  • Simple Fixed Types
  • WLN and SMILES Fragments
  • Atom-Centered Fragments
  • Bond-Centered Fragments
  • Maximum Common Substructures
  • Atom Pairs and Topological Multiplets
  • Substituents and Molecular Frameworks
  • Basic Subgraphs
  • Mined Subgraphs
  • Random Subgraphs
  • Library Subgraphs
  • Fragments describing supramolecular systems and chemical reactions
  • Storage of fragments' information
  • Fragment's Connectivity
  • Generic Graphs
  • Labeling Atoms
  • Application in Virtual Screening and In Silico Design
  • Filtering
  • Similarity Search
  • SAR Classification (Probabilistic) Models
  • QSAR/QSPR Regression Models
  • In Silico Design
  • Limitations of Fragment Descriptors
  • Conclusion
  • 2
  • Topological Pharmacophores
  • Introduction
  • 3D pharmacophore models and descriptors
  • Topological pharmacophores
  • Topological pharmacophores from 2D-aligments
  • Topological pharmacophores from 2D pharmacophore fingerprints
  • Topological index-based 'pharmacophores'?
  • Topological pharmacophores from 2D-aligments
  • Topological pharmacophores from pharmacophore fingerprints
  • Topological pharmacophore pair fingerprints
  • Topological pharmacophore triplets
  • Similarity searching with pharmacophore fingerprints
  • Technical Issues
  • Similarity searching with pharmacophore fingerprints
  • Some Examples
  • Machine-learning of Topological Pharmacophores from Fingerprints
  • Topological index-based 'pharmacophores'?
  • Conclusions
  • 3
  • Pharmacophore-based Virtual Screening in Drug Discovery
  • Introduction
  • Virtual Screening Methods
  • Chemical Feature-based Pharmacophores
  • The Term "3D Pharmacophore"
  • Feature Definitions and Pharmacophore Representation
  • Hydrogen bonding interactions
  • Lipophilic areas
  • Aromatic interactions
  • Charge-transfer interactions
  • Customization and definition of new features
  • Current super-positioning techniques for aligning 3D pharmacophores and molecules
  • Generation and Use of Pharmacophore Models
  • Ligand-based Pharmacophore Modeling
  • Structure-based Pharmacophore Modeling
  • Inclusion of Shape Information
  • Qualitative vs. Quantitative Pharmacophore Models
  • Validation of Models for Virtual Screening
  • Application of Pharmacophore Models in Virtual Screening
  • Pharmacophore Models as Part of a Multi-Step Screening Approach
  • Antitarget and ADME(T) Screening Using Pharmacophores
  • Pharmacophore Models for Activity Profiling and Parallel Virtual Screening
  • Pharmacophore Method Extensions and Comparisons to Other Virtual Screening Methods
  • Topological Fingerprints
  • Shape-based Virtual Screening
  • Docking Methods
  • Pharmacophore Constraints Used in Docking
  • Further Reading
  • Summary and Conclusion
  • 4
  • Molecular Similarity Analysis in Virtual Screening
  • Ligand-Based Virtual Screening
  • Foundations of Molecular Similarity Analysis
  • Molecular Similarity and Chemical Spaces
  • Similarity Measures
  • Activity Landscapes
  • Analyzing the Nature of Structure-Activity Relationships
  • Relationships between different SARs
  • SARs and target-ligand interactions
  • Qualitative SAR characterization
  • Quantitative SAR characterization
  • Implications for molecular similarity analysis and virtual screening
  • Strengths and Limitations of Similarity Methods
  • Conclusion and Future Perspectives
  • 5
  • Molecular Field Topology Analysis in drug design and virtual screening
  • Introduction: local molecular parameters in QSAR, drug design and virtual screening
  • Supergraph-based QSAR models
  • Rationale and history
  • Molecular Field Topology Analysis (MFTA)
  • General principles
  • Local molecular descriptors: facets of ligand-biotarget interaction
  • Construction of molecular supergraph
  • Formation of descriptor matrix
  • Statistical analysis
  • Applicability control
  • From MFTA model to drug design and virtual screening
  • MFTA models in biotarget and drug action analysis
  • MFTA models in virtual screening
  • MFTA-based virtual screening of compound databases
  • MFTA-based virtual screening of generated structure libraries
  • Conclusion
  • 6
  • Probabilistic approaches in activity prediction
  • Introduction
  • Biological Activity
  • Dose-Effect Relationships
  • Experimental Data
  • Probabilistic Ligand-Based Virtual Screening Methods
  • Preparation of Training Sets
  • Creation of Evaluation Sets
  • Mathematical Approaches
  • Evaluation of Prediction Accuracy
  • Single-Targeted vs. Multi-Targeted Virtual Screening
  • PASS Approach
  • Biological Activities Predicted by PASS
  • Chemical Structure Description in PASS
  • SAR Base
  • Algorithm of Activity Spectrum Estimation
  • Interpretation of Prediction Results
  • Selection of the Most Prospective Compounds
  • Conclusions
  • 7
  • Fragment-based de novo design of druglike molecules
  • Introduction
  • From Molecules to Fragments
  • From Fragments to Molecules
  • Scoring the Design
  • Conclusions and Outlook
  • 8
  • Early ADME/T predictions: a toy or a tool?
  • Introduction
  • Which properties are important for early drug discovery?
  • Physico-chemical profiling
  • Lipophilicity
  • Solubility
  • Data availability and accuracy
  • Models
  • Why models don't work: the challenge of the Applicability Domain
  • AD based on similarity in the descriptor space
  • AD based on similarity in the property-based space
  • How reliable are predictions of physico-chemical properties?
  • Available Data for ADME/T biological properties
  • Absorption
  • Data
  • Models
  • Distribution
  • Data
  • Models
  • The usefulness of ADME/T models is limited by available data
  • Conclusions
  • 9
  • Compound Library Design
  • Principles and Applications
  • Introduction to Compound Library Design
  • Methods for Compound Library Design
  • Design for Specific Biological Activities
  • Similarity Guided Design of Targeted Libraries
  • Diversity Based Design of General Screening Libraries
  • Pharmacophore Guided Design of Focused Compound Libraries
  • QSAR Based Targeted Library Design
  • Protein Structure Based Methods for Compound Library Design
  • Design for Developability or Drug-likeness
  • Rule & Alert Based Approaches
  • QSAR Based ADMET Models
  • Undesirable Functionality Filters
  • Design for Multiple Objectives and Targets Simultaneously
  • Concluding Remarks
  • 10
  • Integrated Chemo- and Bioinformatics Approaches to Virtual Screening
  • Introduction
  • Availability of large compound collections for virtual screening
  • NIH Molecular Libraries Roadmap Initiative and the PubChem database
  • Other chemical databases in public domain
  • Structure based virtual screening
  • Major methodologies
  • Challenges and limitations of current approaches
  • The implementation of cheminformatics concepts in structure based virtual screening
  • Predictive QSAR models as virtual screening tools
  • Critical Importance of model validation
  • Applicability domains and QSAR model acceptability criteria
  • Predictive QSAR modeling workflow
  • Examples of application
  • Structure based chemical descriptors of protein ligand interface: the EnTESS method
  • Derivation of the EnTESS descriptors
  • Validation of the EnTESS descriptors for binding affinity prediction
  • Structure based cheminformatics approach to virtual screening: the CoLiBRI method
  • The representation of three-dimensional active sites in multidimensional chemistry space
  • The mapping between chemistry spaces of active sites and ligands
  • Summary and Conclusions.